Navigation Links
Bioniche Converts a Portion of its Debt to Equity

- results in US$1.75 million of new available funds -

BELLEVILLE, ON, March 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Company has exercised its right under the agreement to repay US$1.75 million of its secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) in common shares.

The conversion is in accordance with the formula set out in the original agreement signed in 2005. The shares will be priced at the ten day market average less 15% which equates to 2,671,900 shares. In addition, the Company will issue 200,000 five-year warrants at market price ($0.77 per share) in exchange for Valens waiving certain volume restrictions relating to the conversion under the agreement. There is no penalty attached to this repayment.

This conversion will result in new available funds of US$1.75 million. As a result, the Company's capacity to borrow under the revolving credit facility after the conversion will be approximately US$3.2M, determined by a formula which measures existing levels of inventory and accounts receivable.

"Again we appreciate the support and flexibility of our bankers, Valens U.S.," said Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "This private placement will improve our liquidity as we continue to execute our Phase III clinical development program with Urocidin in bladder cancer and begin the construction of a facility in which to scale-up production of our E. coli O157:H7 cattle vaccine in Belleville, Ontario."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
2. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
3. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
4. Bioniche Reports Fiscal 2008 Second Quarter
5. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
6. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
7. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
8. Bioniche Reports Fiscal 2008 First Quarter
9. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
10. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
11. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: